Deals

Lupin announced US FDA approval for its Armlupeg (pegfilgrastim-unne) biosimilar and a licensing deal with Valorum in a span of a few days.

Hot on the heels of denosumab launches by four suppliers on the first day of December, more biosimilar challengers are piling into the European market with their own rivals to Prolia and Xgeva. And the space is only going to get more crowded as further versions launch.

Zydus inks a new 505(b)(2) oncology deal, taking over the commercialization of RK Pharma’s undisclosed sterile injectable in the US.

Prestige Biopharma has picked Biosidus to manufacture and export its Tuznue biosimilar rival to Herceptin across four Latin American countries.

Deal gives NTC exclusive rights to commercialize Formycon and Klinge’s Baiama aflibercept biosimilar in Italy, expanding Formycon’s growing network of European ophthalmology partners.

Treasurer Jim Chalmers has blocked the AU$677m bid following FIRB advice that the acquisition posed unacceptable risks to Australia’s critical medicine supply chains.

Zydus looks to fill up its coffers ahead of the next round of acquisitions, likely in the specialty drugs space, while US FDA approvals for generics to Lynparza and Vumerity and its first approvals in China and Canada point to a healthy pipeline.

Dr Reddy’s and Bio-Thera have followed up an earlier south-east Asia deal, covering ustekinumab and golimumab biosimilar rivals to Stelara and Simponi, with a further alliance on the Chinese developer’s secukinumab challenger to Cosentyx.

Addressing a major biosimilars opportunity not already accounted for by its pipeline, Sandoz has struck a deal with EirGenix worth up to $152m for rights to the firm’s EG1206A pertuzumab rival to Perjeta – just weeks after the EMA and FDA said a Phase III trial for the product could be waived.

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call.

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.

Expounding on the scale of the potential opportunity for biosimilars developers as the firm delivered its third-quarter results, Sandoz also set out launch plans for denosumab and aflibercept in Europe, as well as natalizumab in the US, by year-end.

Strides and Incepta’s partnership on the first generic injectable contraceptive marks a leap forward for many women in Africa to take control of their reproductive rights.

Just days after receiving FDA approval for its Eydenzelt biosimilar rival to Eylea, Celltrion has secured a US aflibercept launch date through a settlement with originator Regeneron. Meanwhile, new launches have helped to boost the Korean firm’s financials in Q3.

Aspire Pharma is expanding again, with the acquisition of fellow UK firm and niche generics developer Charlwood Pharma.

Through an expansion of their partnership, Biocon Biologics and Civica Rx are planning to launch a private-label version of insulin glargine in the US from January – at a price that equates to just $11 per pen.

Formycon and its aflibercept biosimilar partner Klinge shook hands with Actor Pharmaceuticals and Megalabs to market the Eylea rival in their respective regions.

Bio-Thera and Accord build on their North American golimumab biosimilar partnership, with Canada being a valuable market for both firms.

In a detailed interview, Aurobindo’s European CEO Venugopalan Muralidharan – Murali – explains how the firm is increasingly focusing on complex products such as injectables and biosimilars, as well as eyeing upcoming opportunities such as GLP-1s and ADCs, while also remaining open to potential M&A.

Natco Pharma has inched closer to completing its planned INR20bn acquisition of a 35.75% stake in South Africa’s Adcock Ingram, after the latter’s shareholders overwhelmingly approved a scheme of arrangement, with 98.66% votes in favor.